

June 3, 2026

The Manager- Listing

BSE Limited

Corporate Relationship Dept., 5th Floor, New Trading Ring
Rotunda Building, P J Towers, Dalal Street, Fort
Mumbai - 400001

The Manager- Listing

National Stock Exchange of India Limited

Exchange Plaza, 5th Floor, Plot No. C/1, G Block
Bandra –Kurla Complex, Bandra (E)
Mumbai - 400051

Dear Sir/ Madam,

Sub: Intimation under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulation, 2015

Pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, and in furtherance to our earlier intimations to the stock exchanges dated June 21, 2024, regarding the exit from the manufacturing site, and September 2, 2025, regarding the surrender of the manufacturing license, we hereby inform that an Administrative Committee of the Board of Directors of AstraZeneca Pharma India Limited ('the Company'), has today approved the surrender its factory license, which was valid up to December 31, 2026, to the Department of Factories, Boilers, Industrial Safety and Health for cancellation.

Please find the details as required under the SEBI Circular No. HO/49/14/14(7)2025 - CFD-POD2/I/3762/2026 dated January 30, 2026, attached herewith as **Annexure – A**.

We request you to take the above intimation on record.

Thanking you,

For **AstraZeneca Pharma India Limited**

Tanya Sanish

Company Secretary & Compliance Officer

Annexure - A

Sl. No.	Particulars	Details
1	Name of the regulatory or licensing authority	Department of Factories, Boilers, Industrial Safety and Health.
2	Brief details of the approval/license obtained/ withdrawn/ surrendered	The Company has surrendered its factory license, which was valid up to December 31, 2026, to the Department of Factories, Boilers, Industrial Safety and Health for cancellation.
3	Impact/relevance of such approval/license to the listed entity	Not applicable
4	Withdrawal/cancellation or suspension of license/approval by the regulatory or licensing authority, with reasons for such action, estimated impact (monetary or otherwise) on the listed entity and penalty, if any	Not applicable
5	Period for which such approval/license is/was valid	The license is valid for a period from December 14, 2023 to December 31, 2026.
6	Actual impact (monetary or otherwise) along with corrective actions taken by the listed entity pursuant to the withdrawal, cancellation or suspension of the key license/ approval	Not applicable